SLR Investment Corp. (SLRC) Q3 2026 earnings review
SLR Investment originates record loans, but write-downs cut book value
SLR Investment Corp., a lender to mid-sized US businesses, grew its loan book again even as loan write-downs trimmed its book value. Co-chief executive Michael Gross reported record loan originations of $575 million, which outpaced repayments and lifted the comprehensive portfolio 4% from June. Net investment income held steady at $0.33 per share, covering the $0.31 dividend.
| Total investment income | $49.3M -13.4% from a year ago |
|---|---|
| Net investment income per share | $0.33 flat from last quarter |
| Net asset value per share | $17.83 -$0.17 from last quarter |
| Quarterly dividend plan | Unchanged $0.31 per share for Q4 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because strong lending and October share buybacks balanced out higher borrowing costs and credit marks. Management spent $10 million after quarter-end to retire nearly 2% of its shares below book value, answering a long-standing shareholder complaint. The bad news: refinancing $135 million of expiring debt at 6.76% adds nearly $5 million in annual interest by our math, while another $10 million in portfolio write-downs pushed a loan into the lowest risk tier.
The question now is whether the expanding loan book can lift per-share profit above $0.33 over the next year or if debt repricing and fee rules will keep earnings pinned. Either revenue from new loans clears the manager's fee threshold, or higher interest bills eat up the extra income. First-quarter net investment income, after the January note refinancing takes effect, will tell.
🐂 Bull Case
Record Lending Grew the Portfolio Again
SLR Investment Corp. lends money to middle-market US businesses and tracks its reach through its comprehensive investment portfolio, which combines loans on its own books with those at its lending subsidiaries. Customer repayments have held back growth in this portfolio for over a year. Co-chief executive Michael Gross said "Ninety-five percent of our record $575 million originations were in specialty finance, and we expect that to continue." Specialty finance means loans backed by specific business assets like inventory, receivables or leased equipment rather than general company cash flow. Software loans stayed below 1% of the portfolio.
- New loans funded: $575.1 million, up from $471.1 million last quarter
- Loans repaid: $429.2 million, compared with $431.4 million last quarter
- Net portfolio additions: $145.9 million, lifting the comprehensive portfolio 4.3% from June to $3.38 billion
- Asset-based loans: up $46.0 million from June to $1.45 billion, still $29.6 million below December by our math
The lending surge matters because gross investment income fell 13.4% from a year ago "primarily due to a decrease in the average size of the income producing investment portfolio". Because repayments stayed high at $429.2 million, one quarter of net growth fades the repayment concern rather than ending it. What to watch: fourth-quarter net additions in asset-based lending. It will show whether the lender can erase the remaining $29.6 million gap to meet its full-year growth goal.
Management Started Buying Back Shares in October
SLR extended a $50 million share repurchase plan in May 2026, but the lender bought back zero shares throughout 2025 and the first nine months of 2026. In October, after the third quarter closed, it spent $10.0 million to buy 884,002 shares. By our math, the lender paid $11.31 per share and retired 1.6% of its stock.
Buying shares below net asset value (NAV), the per-share value of the company's assets minus its debts, raises NAV per share for remaining owners because the company retires $17.83 of book value for every $11.31 spent. What to watch: first-quarter buyback disclosures after the $40 million remaining authorization. Continued purchases would show a lasting shift in how management uses idle capital.
Positives this quarter didn't test
Two standing growth initiatives received no new operating detail in the third-quarter earnings release and await the conference call or quarterly filing.
- Acquisitions of asset-based lending platforms and bank sourcing partnerships: not mentioned in the release; any closed deal or volume figure on the call would test whether inorganic growth can speed up portfolio expansion.
- Life-science lending team expansion: new hires were cited last quarter as a driver of a larger deal pipeline, and fourth-quarter originations will show whether that pipeline turns into funded loans.
🐻 Bear Case
New Debt Costs Nearly Double the Expiring Rate
SLR funds roughly half its investments with borrowed money and pays its external manager an incentive fee that absorbs profit changes when net investment income sits near $0.33 per share. The lender has $260 million of low-rate unsecured notes maturing between December 2026 and March 2027. On October 28, it committed to issue $135 million of new unsecured notes due in June 2030 at a fixed interest rate of 6.76%, matching the $135 million note maturing in January 2027 that carries a 3.33% rate.
- Interest and credit facility costs: 35.0% of investment income, up 2.2 percentage points from a year ago by our math
- Performance-based incentive fees: 7.6% of investment income, down 1.8 percentage points from a year ago by our math
- Annual interest increase on the $135 million note: $4.6 million by our math, or $1.2 million per quarter
The 6.76% coupon is higher than the 5.95% to 6.14% rates on the company's previous note issues. That extra interest bill will keep net investment income pinned near $0.33 per share because portfolio income must first outrun higher borrowing costs and the manager's fee catch-up before shareholders see per-share profit grow. What to watch: the interest rate on the remaining $125 million of notes maturing in December and March. Refinancing them near 6.8% would add another $3 million of annual interest cost.
Loan Write-Downs Cut Net Asset Value Again
"We continue to have high conviction in the stability and credit quality of our portfolio," co-chief executive Bruce Spohler said. He noted that only two investments sit on non-accrual — loans where the borrower is behind and the lender stops booking interest — and that only 2% of gross income comes from payment-in-kind (PIK) interest "resulting from amendments", where a struggling borrower pays interest with more debt instead of cash.
The accounting marks tell a tougher story. SLR recorded $10.5 million of net unrealized losses this quarter, including $15.4 million of write-downs on standard portfolio companies where it owns less than 5%. Those losses cut NAV by $0.17 per share to $17.83, following a $0.16 drop last quarter. Loans in internal rating 4, the highest risk tier where full principal recovery is doubtful, rose from zero in June to $6.9 million.
Write-downs erode the equity base that sets the lender's borrowing limit and fee thresholds. What to watch: the company names in the rating 3 and rating 4 buckets when the quarterly 10-Q filing arrives. It will show whether the $15.4 million loss came from the two known non-accruals or from new troubled borrowers.
Life-Science Lending Still Shrank Despite New Hires
Life-science loans are senior secured loans to drug developers and medical-device makers. They used to be one of SLR's highest-yielding niches, but new rival lenders have crowded the market over the past year. Last quarter management said it was hiring staff to rebuild the book.
Third-quarter life-science originations fell to $5.0 million from $24.5 million in the second quarter. Even with zero repayments, the life-science portfolio's fair value dropped from $187.6 million in June to $175.7 million in September, and the segment's income contribution fell 25.0% from a year ago to $5.1 million. What to watch: fourth-quarter life-science originations. Another quarter near $5 million would show that competition still blocks the segment's recovery.
👓 Other Themes
Fixed-Rate Leasing Cushions the Portfolio Against Rate Cuts
Gross said the portfolio fits a higher-for-longer interest rate environment. Floating-rate loans made up 61.9% of the income-producing comprehensive portfolio at September 30, down from 63.1% in June and 65.9% a year ago, because equipment leases carry fixed rates. That fixed-rate mix helped lift the average yield on senior secured loans to 11.2% from 11.1% in June.
💲 Other KPIs
Non-discretionary unfunded commitments — approved credit lines that borrowers can draw down at will — fell 5.1% from June and 16.5% from a year ago. The balance has dropped for three straight quarters from $316.3 million last September, which means borrowers have less pre-approved credit left to tap without new loan originations.
On-balance-sheet debt fell 4.1% from June's $1,153.7 million and 3.5% from December's $1,146.4 million. The business development company had $627.9 million drawn on its $995 million revolving credit lines, $143.3 million in term loans, and $484 million in unsecured notes, leaving over $850 million of total borrowing capacity across the group.
SLR Senior Lending Program (SSLP), the 50-50 lending venture with Sunstone Senior Credit, paid the US lender $1.3 million in the third quarter. That equals an 11.0% annualized yield on cost, down from 11.8% in the second quarter and 12.2% in the first quarter, as repayments of $9.8 million topped the $7.0 million of new loans funded.
🔮 Guidance
Unchanged. The board declared a $0.31 per share cash payout for the fourth quarter, matching the level set in the first quarter when the dividend was cut from $0.41. Third-quarter net investment income of $0.33 per share covered the payout with two cents to spare.
Unchanged. Management kept its target leverage band at 0.90x to 1.25x debt-to-equity. Actual leverage fell to 1.10x in September from 1.16x in June and 1.14x in December, leaving room to borrow another $146 million before hitting the top of the band.
❓ Key Questions
Which borrowers drove the $15.4 million unrealized loss?
Companies under 5% owned had $15.4 million of unrealized write-downs in the third quarter, and internal rating 4 loans rose from zero to $6.9 million. Investors need to know if this reflects deeper losses on existing non-accruals or new troubled loans.
How will SLR refinance the December and March notes?
The October private note offering covers the $135 million January 2027 maturity at 6.76%, but $75 million matures in December 2026 and $50 million in March 2027. Management has not said whether it will use its revolving credit line or issue more notes.
What triggered the October share buybacks, and will they continue?
After buying zero shares for seven straight quarters, the company spent $10.0 million to repurchase 884,002 shares in October. Shareholders need to hear what price or leverage threshold governs the remaining $40 million buyback authorization.
Why did life-science loan originations drop back to $5 million?
Management said last quarter that new hires had lifted its life-science pipeline by 20%, yet third-quarter originations fell to $5.0 million from $24.5 million in the second quarter, and the book's fair value shrank by $11.9 million.